New insights reveal the profound impact of acne and the growing interest in modern treatments

Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announces the release of important new acne survey data as part of June’s Acne Awareness Month. The findings highlight the impact of acne on individuals and emphasize the substantial role of novel treatments like AviClear®, the first FDA-cleared energy-based device for the long-term treatment of mild, moderate, and severe inflammatory acne, in improving quality of life.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613634097/en/

(Graphic: Business Wire)

Cutera’s acne survey data¹ sheds light on the emotional and physical aspects of acne in day-to-day life including the effect on memory-making moments, and the importance of new approaches in treating acne.

The survey data highlights the following key insights¹:

• 90% of acne sufferers surveyed experience daily insecurities related to their acne.
• 43% of acne sufferers surveyed worry they will never have clear skin.
• 6 in 10 say the struggles in treating acne can be worse than the acne itself.
• Half of those who have heard of AviClear are interested in trying it.

The survey data also revealed that 81% of acne sufferers surveyed wish they knew more about in-office treatments, with lasers being the #1 acne treatment that sufferers are considering¹. This data validates the market demand that Cutera proactively identified, ultimately leading to the development of AviClear, a solution that effectively addresses the significant gap in acne treatment options.

“At Cutera, we believe in transforming lives through the advancement of our technologies,” said Taylor Harris, CEO of Cutera. “We understand the significant toll that acne has on individuals, and we are dedicated to introducing treatments like AviClear that help people overcome insecurities and embrace life with confidence. We continue to invest in research and innovation, driven by our passion to make a meaningful impact on the lives of those we serve.”

Additional Acne Awareness Month activities include:

• AviClear investor webinar at 11 a.m. PDT on June 20, 2024; the webinar will include a review of clinical data, market opportunity, future clinical studies, and real-world user experience. To attend the live webinar or access the recording please visit www.cutera.co/aviclearinvestor
• Cutera Acne Impact Report with full survey data available at the end of June
• AviClear Acne Awareness Sweepstakes: Consumers can share anecdotes of missed moments due to acne for the chance to win $500²

For more information on AviClear, please visit www.aviclear.com.

About Cutera, Inc.

Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera strives to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1-888-4-CUTERA or visit Cutera.com.

Important safety and risk information about AviClear is available by contacting Cutera at www.cutera.com/us-en/global-offices. Patients should talk to their healthcare provider.

¹2024 Cutera Acne Survey

(For the Cutera Acne Survey, Cutera partnered with PR and Digital Marketing Agency EvolveMKD and survey vendor FocalData to digitally survey 500 acne sufferers in the U.S.)

²NO PURCHASE OR PAYMENT NECESSARY TO ENTER OR WIN. Open to legal residents of the 50 U.S./D.C., age 18+. Void outside the 50 U.S./D.C. and where prohibited. Sweepstakes starts at 12:00:00 AM PT on 6/3/24; ends at 11:59:59 PM PT on 7/14/24. Limit: One (1) entry per person per day. Odds of winning depend on the number of entries received per Weekly Entry Period. For full Official Rules, visit www.cutera.co/avisweeps. Sponsor: Cutera, Inc., 3240 Bayshore Boulevard, Brisbane, CA 94005. $500 to be awarded as a digital, pre-paid bank gift card.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613634097/en/